AI drug discovery company Relay Therapeutics has secured USD 30 million as private investment in public equity from Nextech in return for 2.5 million shares sold at a price of USD 12.00 per share. The transaction is expected to close by January 10, 2024.
The proceeds will be utilized to expand the development of RLY-2608, a drug to treat breast cancer, and to cover working capital and other corporate needs.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.